1. Academic Validation
  2. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates

  • Antimicrob Agents Chemother. 2009 Nov;53(11):4915-20. doi: 10.1128/AAC.00078-09.
Heather J Adam 1 Nancy M Laing C Richard King Ben Lulashnyk Daryl J Hoban George G Zhanel
Affiliations

Affiliation

  • 1 Department of Clinical Microbiology, Health Sciences Centre, MS673-820 Sherbrook St., Winnipeg, Manitoba R3A 1R9, Canada. hadam@hsc.mb.ca
Abstract

The in vitro activity of nemonoxacin (TG-873870), a novel nonfluorinated Quinolone, was tested against 2,440 clinical isolates. Nemonoxacin was at least fourfold more active than levofloxacin and moxifloxacin against most gram-positive cocci tested (shown by the following MIC(90)/range [microg/ml] values; community-associated methicillin [meticillin]-resistant Staphylococcus aureus, 0.5/0.015 to 2; Staphylococcus epidermidis, 0.5/0.015 to 4 for methicillin-susceptible staphylococci and 2/0.12 to 2 for methicillin-resistant staphylococci; Streptococcus pneumoniae, 0.015/< or = 0.008 to 0.25; Enterococcus faecalis, 1/0.03 to 128). Nemonoxacin activity against gram-negative bacilli was similar to levofloxacin and moxifloxacin (MIC(90)/range [microg/ml]; Escherichia coli, 32/< or = 0.015 to > or = 512; Klebsiella pneumoniae, 2/< or = 0.015 to 128; K. oxytoca, 0.5/0.06 to 1; Proteus mirabilis, 16/0.25 to > or = 512; Pseudomonas aeruginosa, 32/< or = 0.015 to > or = 512; Acinetobacter baumannii, 1/0.12 to 16).

Figures
Products